Effects of tyrosine kinase inhibitors and CXCR4 antagonist on tumor growth and angiogenesis in rat glioma model: MRI and protein analysis study. - Wikidata - awgldk - TriplyDB

Effects of tyrosine kinase inhibitors and CXCR4 antagonist on tumor growth and angiogenesis in rat glioma model: MRI and protein analysis study.

Effects of tyrosine kinase inhibitors and CXCR4 antagonist on tumor growth and angiogenesis in rat glioma model: MRI and protein analysis study.

http://www.wikidata.org/entity/Q37474359

about

G protein-coupled receptors as oncogenic signals in glioma: emerging therapeutic avenues Targeting autophagy to sensitive glioma to temozolomide treatment Phosphatidylcholine-specific phospholipase C inhibition down- regulates CXCR4 expression and interferes with proliferation, invasion and glycolysis in glioma cells.CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment.Vascular Mimicry: A Novel Neovascularization Mechanism Driving Anti-Angiogenic Therapy (AAT) Resistance in Glioblastoma IL-24 inhibits lung cancer cell migration and invasion by disrupting the SDF-1/CXCR4 signaling axis Bone marrow derived myeloid cells orchestrate antiangiogenic resistance in glioblastoma through coordinated molecular networks.Combination of vatalanib and a 20-HETE synthesis inhibitor results in decreased tumor growth in an animal model of human glioma.Targeting Bone Marrow to Potentiate the Anti-Tumor Effect of Tyrosine Kinase Inhibitor in Preclinical Rat Model of Human Glioblastoma.Targeted Theranostic Approach for Glioma Using Dendrimer-Based Curcumin Nanoparticle.Targeting Glioma with a Dual Mode Optical and Paramagnetic Nanoprobe across the Blood-brain Tumor Barrier p53 Mutation: Critical Mediator of Therapy Resistance against Tumor Microenvironment.Targeting Triple Negative Breast Cancer with a Small-sized Paramagnetic Nanoparticle.The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma.Anti-VEGFR2 driven nuclear translocation of VEGFR2 and acquired malignant hallmarks are mutation dependent in glioblastoma.Intravenous Formulation of HET0016 Decreased Human Glioblastoma Growth and Implicated Survival Benefit in Rat Xenograft Models Chimeric Mouse model to track the migration of bone marrow derived cells in glioblastoma following anti-angiogenic treatments.Vascular Mimicry: The Next Big Glioblastoma Target.Major Challenges and Potential Microenvironment-Targeted Therapies in Glioblastoma.The role of tumor microenvironment in resistance to anti-angiogenic therapy.

P2860

Q26825769-8BB15DF1-F7C3-4BB9-A9AD-9C5DC452B827 Q28066270-F379A2EA-2386-408F-83C6-A654EF5F7A8E Q33580152-9E568EC7-CEFF-4368-8ED0-A94C4947219C Q33677057-66D31F03-BCE8-44EB-98EC-4894AC052124 Q33868524-662299C1-4513-4691-B6E4-514298B6D0E3 Q35578377-B7E997D2-5B24-41B9-BE45-995F4D30E12E Q36390700-91182564-B59E-4BA9-896D-DA1153D3CDA7 Q36684023-C718E181-3ED9-492E-B950-53A312DEC8FC Q37095230-F61E5C7A-540F-463C-9364-CD38FBE9B6A0 Q37292721-136C645F-6611-4FA3-B997-88832C4F3F60 Q37296161-B60DAD63-0D9D-46F5-86FC-70A99C73936E Q37468744-4226190D-2518-4A4D-9F94-17C09064D121 Q37529757-F18659B7-4589-4E22-86DB-4E1A0A46A43A Q37567174-5A2D046E-40DE-406B-BFDD-62BB18EB61D9 Q37613594-4DE72A36-662C-4DE1-B130-2761F21DFDC9 Q37615383-4A674EA8-E8A1-43AE-8BEA-4E88C164B57D Q38800593-4D3AB6E4-E2EF-4CC7-91A3-C0B4AA519A9F Q39691814-9D8D934D-2AFB-440E-BC73-3C65EA00C4B7 Q47773621-511125F2-0BEE-4898-8E1C-40042AE922C4 Q52645823-B258567F-1BB7-486A-BA63-DA8429E5D5D4

P2860

Effects of tyrosine kinase inhibitors and CXCR4 antagonist on tumor growth and angiogenesis in rat glioma model: MRI and protein analysis study.

http://www.wikidata.org/entity/Q37474359

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Effects of tyrosine kinase inh ...... RI and protein analysis study.

@en

Effects of tyrosine kinase inh ...... RI and protein analysis study.

@nl

type

label

Effects of tyrosine kinase inh ...... RI and protein analysis study.

@en

Effects of tyrosine kinase inh ...... RI and protein analysis study.

@nl

prefLabel

Effects of tyrosine kinase inh ...... RI and protein analysis study.

@en

Effects of tyrosine kinase inh ...... RI and protein analysis study.

@nl

P1433

Q37474359-22977D39-C2AE-4B80-BB97-0933A40BE792

P1476

Q37474359-E3CC9985-CB37-4694-B27D-B1638CC3EC9B

P2093

Q37474359-2663B630-D0CE-4225-8DDD-19138B5FCB6D

Q37474359-2A4EF20B-3919-4C81-82A1-F3227C933522

Q37474359-34095192-5CA7-41D9-9A23-55759713656D

Q37474359-4B9044F0-9485-4DFA-AD68-D69DE36FCC41

Q37474359-5737E401-77A1-4087-8FEB-4176A3E8E2B5

Q37474359-5E8574FA-100A-4B46-BA5B-C5785EAA423E

Q37474359-674CF173-9D31-43E2-BBA5-36724BC8DC83

Q37474359-891E65DF-5156-4566-852F-771561CD8DE7

Q37474359-94FCB094-7BC0-472A-8A2E-934129AE81B6

Q37474359-C0E43D1E-1330-4ACD-857B-1B6EA2337E7A

P2860

Q37474359-1102AE46-174E-4BCF-8EAC-3A3D1FF34F45

Q37474359-1E18B923-6CBB-4834-84F3-C43741930082

Q37474359-1E7FBC1F-B737-4972-A123-1628A5952C7E

Q37474359-21100C3F-E3DD-48BB-9ADE-46B07E7E4F41

Q37474359-29D9CA49-E833-43CA-9F10-3A2F09DA0AE2

Q37474359-2B39DA91-F662-43EC-83B4-05CAF6F5AA6B

Q37474359-325EC530-1F7C-452F-9F30-6C478075FC0A

Q37474359-36F299EC-DE33-409E-A459-67AB0655B3CA

Q37474359-50F52C79-219B-485C-B981-D6562DD1B61F

Q37474359-52F96058-27C1-4161-9210-D77BCBE50003

P304

Q37474359-6292427F-DCCD-4138-9D93-23FA954C860B

P31

Q37474359-81D0EF72-3897-43BA-A79C-00DA16E42DF9

P356

Q37474359-3561BEC0-03F5-43B1-B00C-9124921251BF

P433

Q37474359-370202F8-D632-46EA-A554-7FD0B7DEE114

P478

Q37474359-A13E79A6-B4B6-4647-A0B7-B39C7414FDE4

P50

Q37474359-4FA51AD2-073C-4D45-B011-6614380E60EB

Q37474359-8532BD66-71B6-467C-BC46-0F2C7CC5F42C

P577

Q37474359-DBD52027-C9F3-4C2E-AECD-C3512B0ECF82

P5875

Q37474359-76C01E4F-A198-4DC7-8EAD-69BB54AE2556

P698

Q37474359-3400BFFD-45DE-4FD9-95A8-C09407CDE89E

P932

Q37474359-6EB7D007-6EC6-425D-A513-1AD0DAC57B0C

P356

P1433

Translational Oncology

P1476

Effects of tyrosine kinase inh ...... MRI and protein analysis study

@en

P2093

A S M Iskander

http://www.w3.org/2001/XMLSchema#string

Abbas Babajeni-Feremi

http://www.w3.org/2001/XMLSchema#string

Adarsh Shankar

http://www.w3.org/2001/XMLSchema#string

Ali S Arbab

http://www.w3.org/2001/XMLSchema#string

Branislava Janic

http://www.w3.org/2001/XMLSchema#string

Hassan Bagher-Ebadian

http://www.w3.org/2001/XMLSchema#string

James R Ewing

http://www.w3.org/2001/XMLSchema#string

Meser M Ali

http://www.w3.org/2001/XMLSchema#string

Nadimpalli R S Varma

http://www.w3.org/2001/XMLSchema#string

Sanath Kumar

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice.

Identification of uPAR-positive chemoresistant cells in small cell lung cancer

Patlak plots of Gd-DTPA MRI data yield blood-brain transfer constants concordant with those of 14C-sucrose in areas of blood-brain opening.

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

CXCR4 expression mediates glioma cell invasiveness.

EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma.

Phase II study of sunitinib malate in patients with recurrent high-grade glioma.

Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.

A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma.

Changes in vascular permeability and expression of different angiogenic factors following anti-angiogenic treatment in rat glioma

P304

660-669

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1593/TLO.13559

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259920493

http://www.w3.org/2001/XMLSchema#string

P698

24466368

http://www.w3.org/2001/XMLSchema#string

P932

3890700

http://www.w3.org/2001/XMLSchema#string